Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Recombinant Vaccines Market generated $8.1 billion in 2021 and is estimated to hit $24.7 billion by 2031, registering a CAGR of 11.4% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.
Download Free Sample Report (258 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/18055
Report coverage & details:
| Report Coverage | Details |
| Forecast Period | 2022–2031 |
| Market Size in 2031 | $24.7 billion |
| CAGR | 11.4% |
| No. of Pages in Report | 258 |
| Drivers | Increase in research and development activities for recombinant vaccines |
| Rise in prevalence of infectious and zoonotic diseases | |
| Emerging technologies for developing vaccines | |
| Surge in number of product approvals | |
| Opportunities | The high growth potential in untapped emerging economies |
Covid-19 scenario-
- The Covid-19 pandemic positively impacted the recombinant vaccines market. The introduction of Covid-19 vaccines was a major step toward reducing the spread of the virus and the associated disease and deaths. Governments across the world ensured seamless delivery of Covid-19 recombinant vaccines to the prioritized group.
- For the vaccine development, the World Health Organization (WHO) facilitated the collaboration and accelerated efforts on an unprecedented scale and convened vital communications across the research communities. The increase in the research and development activities proved to be beneficial for the development of effective vaccines.
- Moreover, the advantageous effects of vaccination on the population facilitated the production of new and novel vaccines during the pandemic.
The report offers a detailed segmentation of the global recombinant vaccines market based on indication, end user, distribution channel, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.
Based on indication, the human papillomavirus segment accounted for nearly three-fourths of the overall recombinant vaccines market in 2021, and is projected to lead the trail by the end of 2031. Moreover, the same segment is expected to grow at a CAGR of 12.2% during the forecast period. The report also analyzes meningococcal and others segments.
Purchase Inquiry:
https://www.alliedmarketresearch.com/purchase-enquiry/18055
Based on end user, the adults segment contributed to more than three-fifths of the global recombinant vaccines market in 2021, and is expected to maintain its dominance through 2031. However, the pediatric segment is likely to garner the fastest CAGR of 12.0% during the forecast period.
Based on distribution channel, the hospitals segment captured the largest share of more than four-fifths of the global recombinant vaccines market in 2021, and is likely to exhibit a noteworthy growth during the forecast period. The same segment is likely to achieve a CAGR of 11.7% through 2031. The report also analyzes the vaccination centers segment.
Based on region, the market across North America contributed to nearly two-fifths of the total recombinant vaccines market in 2021, and is expected to maintain its dominance during the forecast period. Asia-Pacific, on the other hand, would grow at the fastest CAGR of 12.5% from 2022 to 2031. The other two provinces discussed in the report include Europe and LAMEA.
The key market players analyzed in the global recombinant vaccines market report include AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd.
The report analyzes these key players of the global recombinant vaccines market. These players have adopted various strategies such as expansion, new product launches, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.
Trending Reports in Healthcare Industry (Book Now with 10% Discount):
Pharmaceutical Packaging Market by Product Type (Parenteral Containers, Plastic Bottles, Blister Packaging, Closures, Specialty Bags, Labels, and Others), Material (Glass, Aluminum Foils, Plastics and Polymers, Paper & Paperboards, and Others): Opportunity Analysis and Industry Forecast, 2020-2027
Point of Care Diagnostics Market by Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Drugs Abuse Testing Kits, Others), by Mode Of Prescription (Prescription Based Devices, Otc Based Devices), by End User (Professional Diagnostic Centers, Research Laboratories, Home Care, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020-2027
Digital Therapeutics Market by Product (Software and Devices), Sales Channel (Business-to-Business and Business-to-Consumers), Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS), Disease Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID) and Others: Global Opportunity Analysis and Industry Forecast, 2022-2031
Flow Cytometry Market by Component (Instruments, Reagents and consumables, Software, Services), by Technology (Cell based flow cytometry, Bead based flow cytometry), by Application (Academic and clinical applications, Diagnostic applications), by End User (Hospitals, Medical schools and clinical testing labs, Commercial organizations, Academic institutions, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
